|
Reykjavik, Iceland, December 13, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, December 13, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, November 20, 2002
|
|
|
|
deCODE will apply its expertise in in vitro
pharmacogenomics to provide gene expression data in relation to
a Wyeth candidate treatment for respiratory disease
|
|
|
| |
|
Reykjavik, Iceland, November 14, 2002
|
|
|
|
Merck alliance, strong cash position, reductions
in overhead underscore execution of product development strategy
|
|
|
| |
|
Reykjavik, Iceland, November 11, 2002
|
|
|
|
Highlights deCODE's capabilities in structural
biology and x-ray protein crystallography; may enable design of
more effective anti-cancer compounds
|
|
|
| |
|
Reykjavik, Iceland, November 6, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, September 27, 2002
|
|
|
|
Alliance brings together world-leading capabilities
in genetics and drug development to speed the discovery of new
treatments
|
|
|
| |
|
Reykjavik, Iceland, September 27, 2002
|
|
|
|
Leverages strong revenues and significant
productivity gains in genetics research to build self-sustaining
drug and diagnostic target discovery operation
|
|
|
| |
|
Reykjavik, Iceland, August 13, 2002
|
|
|
|
Strong genomics and service businesses deliver
triple-digit revenue growth; Company reiterates year-end goals
and solid business development outlook
|
|
|
| |
|
Reykjavik, Iceland, August 8, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, July 24, 2002
|
|
|
|
Research yields promising drug targets impacting
underlying biology of the disease; Findings form the basis of deCODE's
most advanced drug discovery program
|
|
|
| |
|
Reykjavik, Iceland, July 17, 2002
|
|
|
|
Discoveries will be used to develop novel
diagnostic tools and therapies for asthma and allergies, and to
optimize patient benefit from existing drugs
|
|
|
| |
|
Reykjavik, Iceland and San Diego, CA, July
1, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, June 26, 2002
|
|
|
|
deCODE study published this month reveals
the strongest genetic linkage ever found to the common form of
the condition.
|
|
|
| |
|
Reykjavik, Iceland, June 9, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, May 13, 2002
|
|
|
|
Strong growth underpins downstream development
initiatives; Company on track to meet revenue, business development
targets for the year
|
|
|
| |
|
Reykjavik, Iceland, May 13, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, May 3, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 9, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, March 18, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, March 15, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, March 13, 2002
|
|
|
|
New alliances drive strong revenue growth;
financing of capital expenditures reinforces cash resources for
downstream initiatives
|
|
|
| |
|
Reykjavik, Iceland, March 11, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, February 22, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland and Woodridge,
Illinois, February 21, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland and Basil, Switzerland,
January 29, 2002
|
|
|
|
Alliance will leverage deCODE's expanded
drug development capabilities to turn gene discoveries under existing
collaboration into new drugs for common diseases
|
|
|
| |
|
Reykjavik, Iceland, January 15, 2002
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland and Woodridge, Illinois,
January 8, 2002
|
|
|
|
Acquisition of integrated chemistry capabilities
to accelerate deCODE's growth into a fully-integrated biopharmaceutical
company
|
|
|
| |
|
Reykjavik, Iceland, January 4, 2002
|
|
|
|
|
|
|
| |
